This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of Cenicriviroc (CVC) for the treatment of Stage 2 to 3 liver fibrosis in adult subjects with Non-Alcoholic Steatohepatitis (NASH). The study will be conducted in 2 parts: Part 1 (surrogate endpoint) and Part 2 (clinical outcomes). Part 1: Approximately 1000 subjects will be randomized. Approximately 667 subjects are to receive CVC and approximately 333 subjects are to receive placebo. Subjects who remain in Part 1 at Month 12 will continue to receive the same treatment assignment in Part 2.

Basic Research

Basic Research

Basic Research

Basic Research

This is a multiple-center evaluation of NGM282 in a randomized, double-blind, placebo-controlled, parallel-group study and/or an open-label single-blind cohort when administered for 12 weeks as a daily SC injection in patients with histologically confirmed NASH. Patients to be studied will have histologically confirmed NASH as defined by the NIH NASH Clinical Research Network and determined by a qualified site pathologist.

The major goal of this project is the development of qualified animal models for Sudan Ebola Virus disease. Txbiomed Project: 4699

The major goal of this project is the development of qualified animal models for Sudan Ebola Virus disease.

This study will determine the impact of HIV on M.tb-induced granuloma-like structures. We plan to measure the effect of HIV infection on pre-formed M.tb granuloma structure and function as well as determine how pre-existing HIV infection affects subsequent M.tb-induced granuloma formation and function. Txbiomed Project: 4671

This is a multicenter, double-blind, randomized, placebo-controlled, dose-response study to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite clinical endpoint (where all-cause mortality, new decompensation events, and MELD score progression are events) in subjects with decompensated NASH cirrhosis.